| Name | Title | Contact Details |
|---|---|---|
Barry Steele |
Chief Financial Officer | Profile |
Med-Valu, Inc. is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Bottom Line Benefits is a Acworth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MD Care is a Los Alamitos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As a company, we believe in digital health for everyone everywhere. We have created a new category of therapeutic product – the digital health feedback system – to allow people of all ages and cultures to power their own health, taking better care of themselves and each other. We see two trends: First, there are more people with mobile phones than there are with access to clean, running water. Second, chronic, often lifestyle-related diseases like diabetes are the world’s biggest healthcare problem, and our health systems can’t cope because they are optimized to treat the acute conditions prevalent decades ago. Our vision is to integrate medicines that treat chronic conditions with mobile technology – via our ingestible sensor – to make healthcare more accessible, manageable and innovative. We believe that by providing the right technology to individuals who deliver and receive healthcare, we can build a more effective healthcare system with new care paradigms focused on daily care and new information-based business models.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.